Other languages CureVac N.V. Deutsche Boerse AG

Equities

5CV

NL0015436031

Real-time Estimate Tradegate Other stock markets 05:38:47 26/06/2024 pm IST			5-day change	1st Jan Change
3.293 ^EUR	-2.92%		+9.90%	-13.28%

24/06	CureVac N.V. Approves the Appointment of Birgit Hofmann as a Member of the Supervisory Board	CI
28/05	CureVac, GSK Begin Dosing in Phase 2 Study for Seasonal Influenza Vaccine Candidate	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CureVac N.V. Approves the Appointment of Birgit Hofmann as a Member of the Supervisory Board	25/06
CureVac Announces Voting Results of General Meeting	25/06
CureVac Announces Voting Results of General Meeting	25/06
Öl- und Bankentitel schwach - EZB wirft Schatten voraus	04/06
XETRA-SCHLUSS/DAX schwächer - der Bund macht Kasse	04/06
CureVac N.V. Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK	28/05
CureVac gibt Impfung des ersten Teilnehmers in einer Phase-2-Studie zur saisonalen Grippe bekannt; Entwicklung in Zusammenarbeit mit GSK	28/05
CureVac gibt Impfung des ersten Teilnehmers in einer Phase-2-Studie zur saisonalen Grippe bekannt; Entwicklung in Zusammenarbeit mit GSK	28/05
CureVac N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	24/05
CUREVAC : Significant cash drain in the Q1	24/05
Starke Einkaufsmanager verderben Nvidia-Laune	23/05
CureVac veröffentlicht Finanzergebnisse für das erste Quartal 2024 und informiert über seine Geschäftsentwicklung	23/05
CureVac veröffentlicht Finanzergebnisse für das erste Quartal 2024 und informiert über seine Geschäftsentwicklung	23/05
CUREVAC : A missed opportunity	03/05
CureVac N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	25/04
CureVac Begins Early Stage Portion of Investigational Vaccine Trial	24/04
Höherer Verlust: Impfstoffhersteller Curevac will effizienter werden	24/04
Biotechfirma CureVac verkleinert sich und streicht 150 Stellen	24/04
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer, Effective June 1, 2024	24/04
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza; Development in Collaboration with GSK	24/04

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

CUREVAC : Significant cash drain in the Q1

May 24, 2024 at 01:19 am IST